Behavioral and biochemical studies in rats following prenatal treatment with β-adrenoceptor antagonists
| Autor: | Zipora Speiser, Moshe Rehavi, Simon Gitter, Irit Gordon |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Male
medicine.medical_specialty Adrenergic receptor Offspring Adrenergic beta-Antagonists Administration Oral Hippocampus Gestational Age Motor Activity Heart Rate Pregnancy Internal medicine Receptors Adrenergic beta Muscarinic acetylcholine receptor Avoidance Learning medicine Animals Birth Weight Pharmacology Fetus business.industry Body Weight Sotalol Antagonist Brain Rats Inbred Strains Atenolol Propranolol Rats Endocrinology Animals Newborn Prenatal Exposure Delayed Effects Pregnancy Animal Female business medicine.drug |
| Zdroj: | European Journal of Pharmacology. 195:75-83 |
| ISSN: | 0014-2999 |
| DOI: | 10.1016/0014-2999(91)90383-2 |
| Popis: | Increased motor activity and poor performance in the active avoidance test were observed in the offspring of rats treated with d1-propranolol or sotalol during pregnancy, but not with atenolol and d-propranolol. All substances were administered in drinking water from days 8–22 of gestation. A significant increase in the density of muscarinic acetylcholine receptors in the hippocampus was found for dl-propranolol and sotalol, at 35 and 20 days of age, respectively. Twenty-day-old pups bom to dl-propranolol-treated rats exhibited a non-significant decrease in the number of β-adrenoceptors in the frontal cortex. Assuming that all the β-adrenoceptor antagonists tested had access to the developing fetal brain, the effect of dl-propranolol and sotalol on behavior could stem from central β 2 -adrenoceptor blockade. In view of the lack of behavioral changes after atenolol, a β 1 -selective adrenoceptor antagonist, it is suggested that the clinical use of β 1 -selective adrenoceptor antagonists during pregnancy might be safer for the fetus than β 2 -adrenoceptor antagonists. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|